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Background: Trypanosoma cruzi, the causal agent of Chagas Disease, affects more than 16 million people in Latin
America. The clinical outcome of the disease results from a complex interplay between environmental factors and
the genetic background of both the human host and the parasite. However, knowledge of the genetic diversity of
the parasite, is currently limited to a number of highly studied loci. The availability of a number of genomes from
different evolutionary lineages of T. cruzi provides an unprecedented opportunity to look at the genetic diversity of
the parasite at a genomic scale.
Results: Using a bioinformatic strategy, we have clustered T. cruzi sequence data available in the public domain
and obtained multiple sequence alignments in which one or two alleles from the reference CL-Brener were
included. These data covers 4 major evolutionary lineages (DTUs): TcI, TcII, TcIII, and the hybrid TcVI. Using these set
of alignments we have identified 288,957 high quality single nucleotide polymorphisms and 1,480 indels. In a
reduced re-sequencing study we were able to validate ~ 97% of high-quality SNPs identified in 47 loci. Analysis of
how these changes affect encoded protein products showed a 0.77 ratio of synonymous to non-synonymous
changes in the T. cruzi genome. We observed 113 changes that introduce or remove a stop codon, some causing
significant functional changes, and a number of tri-allelic and tetra-allelic SNPs that could be exploited in strain
typing assays. Based on an analysis of the observed nucleotide diversity we show that the T. cruzi genome contains
a core set of genes that are under apparent purifying selection. Interestingly, orthologs of known druggable targets
show statistically significant lower nucleotide diversity values.
Conclusions: This study provides the first look at the genetic diversity of T. cruzi at a genomic scale. The analysis
covers an estimated ~ 60% of the genetic diversity present in the population, providing an essential resource for
future studies on the development of new drugs and diagnostics, for Chagas Disease. These data is available
through the TcSNP database (http://snps.tcruzi.org).Background
Trypanosoma cruzi is a protozoan parasite of the order
Kinetoplastida, and the causative agent of Chagas
Disease, one of the so called neglected diseases that dis-
proportionately affect the poor. The disease is endemic
in most Latin American countries, affecting in excess of
8 million people [1]. Chagas disease has a variable clinical
outcome. In its acute form it can lead to death (mostly in
infants), while in its chronic form, it is a debilitating disease
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distribution, and reproduction in any mediummega-esophagus and cardiomyopathy, among others. These
different clinical outcomes are the result of a complex inter-
play between environmental factors, the host genetic back-
ground and the genetic diversity present in the parasite
population. As a result, these different clinical manifesta-
tions have been suggested to be, at least in part, due to the
genetic diversity of T. cruzi [2-5].
The T. cruzi species has a structured population, with a
predominantly clonal mode of reproduction [6], and a con-
siderable phenotypic diversity [7-10]. Through the use of a
number of molecular markers the population has been
divided in a number of evolutionary lineages, also called
discrete typing units. Some markers allow the distinction of
two or three major lineages [11-14], while other experimen-
tal strategies, such as RAPD and multilocus isoenzymetral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
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divisions [15-17] originally designated as DTUs I, IIa, IIb,
IIc, IId, and IIe [16]. Recently, this nomenclature was
revised as follows: TcI, TcII (former TcIIb), TcIII (IIc), TcIV
(TcIIa), TcV (TcIId) and TcVI (TcIIe) [18,19]. Lineages TcV
and TcVI (which include the strain used for the first
genomic sequence of T. cruzi, CL Brener) have a very high
degree of heterozygosity but otherwise very homogeneous
population structures with low intralineage diversity
[20,21]. The currently favoured hypothesis suggests that
these two lineages originated after either one or two inde-
pendent hybridization events between strains of DTUs TcII
and TcIII [21-23].
Knowledge of the genetic variation present in a genome
(i.e. between the two alleles of a diploid individual) or in a
species (i.e. in the population) is of central importance for a
variety of reasons and applications: i) to understand the
evolutionary forces underlying the biological and pheno-
typic properties observed in an individual; ii) to detect cases
of apparent horizontal gene transfer; iii) to assess the poten-
tial for development of resistance when validating a target
for drug development; iv) to prioritize targets for develop-
ment of diagnostics or vaccines; v) in the design of con-
structs for genetic knockout experiments in order to
increase the success rate when targeting specific alleles;
and vi) as genetic markers in association studies or to
further probe the population structure.
The genome sequence of the CL-Brener clone of
T. cruzi was published in 2005 [24], together with
those of two other trypanosomatids of medical import-
ance: Trypanosoma brucei (Sleeping sickness, African
trypanosomiasis) [25] and Leishmania major (Leishmania-
sis) [26]. However, the genome of T. cruzi was a particular
case for a number of reasons: it was obtained from a hybrid
TcVI strain composed of two divergent parental haplotypes;
and it was sequenced using a whole genome shotgun stra-
tegy [24]. This choice of strain and sequencing strategy
resulted in high sequence coverage from the two parental
haplotypes, which were derived from ancestral TcII and
TcIII strains. Because of the high allelic variation found
within this diploid genome, a significant number of contigs
were found to be present twice in the assembly [24]. These
divergent haplotypes, which were assembled separately in
many cases, were the basis of a recent re-assembly of the
genome [27]. As a consequence, it is now possible to
identify the genetic diversity present within this diploid
genome.
More recently a number of whole genome sequencing
data have become available from different strains of
T. cruzi: the draft genomic sequence of the Sylvio X10
(TcI) strain [28], high-coverage transcriptomic data,
from another TcI strain (Westergaard G, and Vazquez
MP, manuscript in preparation), as well as 2.5X WGS
shotgun data from the Esmeraldo cl3 (TcII) strain.To take advantage of the hybrid genome of the
CL-Brener strain, and of other genome and transcriptome
datasets, we designed a bionformatics strategy to obtain
information on the genetic diversity present in these data.
As already observed for a significant number of molecular
markers, each of the alleles identified in the majority of the
polymorphic heterozygous site in strains from hybrid
lineages TcV and TCVI can be observed in homozygosity in
strains from either of the two proposed parental lineages
(TcII and TCIII) [20,21,29-31]. Therefore by uncovering the
diversity within the CL-Brener and Sylvio X10 genomes, we
expect to reveal a significant fraction of the diversity that
can be observed between extant TcI, TcII, TcIII, and TcVI
strains.
In this work we present an initial compilation of a
genome-wide map of genetic diversity in T. cruzi, and its
functional analysis, focussed mostly on protein-coding
regions of the genome.
Results
Sequence clustering, alignment and identification of
polymorphic sites
To identify genetic variation in T. cruzi we took advantage
of available sequence data in public databanks, including
the genome sequence of the CL-Brener and Sylvio X10
strains, expressed sequence-tags and other sequences
submitted by independent authors to these databanks. Our
strategy to map this diversity relied on the generation of
multiple sequence alignments and on the scanning of these
alignments to identify polymorphisms [32]. As mentioned,
the sequence of the T. cruzi genome was obtained using a
whole genome shotgun strategy, from a hybrid clone
(CL-Brener) [24]. Because of the sequence divergence
between alleles of the CL-Brener clone, assembly of this
genome resulted in many cases in the separation of these
alleles into separate contigs [24,27]. This allowed us to align
these sequences and identify sequence differences.
However, because of the repetitive nature of the T. cruzi
genome [24,33], we decided to focus this initial effort on
mapping the genetic diversity in mostly single copy protein
coding loci. These were defined as those sequences repre-
sented by no more than 2 coding sequences from the
CL-Brener (reference) genome in our sequence alignments
(see below).
Sequences used in this work include all the annotated
coding sequences from the reference CL-Brener genome,
and the corresponding coding sequences (CDS) from the
Sylvio X10 genome, as well as other publicly available
sequence data (see Table 1). After clustering sequences by
similarity (see Methods) we obtained 7,639 multiple se-
quence alignments, 71.3% of which had 2 reference coding
sequences from the CL-Brener genome (and therefore most
probably representing single copy loci; see Table 1). Other
alignments contain increasing numbers of reference coding
Table 1 Sequences, alignments and SNPs: summary of
data generated and analyzed in this work
Description Number
Sequences
CL-Brener Reference (CDS); TcVI 25,013
Mapped CDS from Sylvio X10 genome; TcI 4,918
Mapped transcripts from TcI transcriptome 3,486
Mapped reads from Esmeraldo cl3 shotgun; TcII § 134,424
Mapped Expressed Sequence Tags (ESTs) 13,968
Mapped misc GenBank sequences (mRNAs, CDS) 2,038
Alignments
Total 7,639
Containing two reference coding sequences 5,447
SNPs
Total 325,355
With P > 0.70 † 305,993
In good sequence neighborhood * 302,390







Average SNP density †* 2.4 per 100 bp
Indels
Total 28,316
With P > 0.70 † 11,007
In good sequence neighborhood * 10,523
P > 0.70 AND good seq neighborhood †* 1,480
§ reads where at least 50bp matched the reference with >= 95% identity.
† SNPs with probability > 0.7 as assigned by PolyBayes [34].
* SNP is located in a 10 bp window with < 2 other SNPs.
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for most of the large gene families of T. cruzi, and were
not considered further. Even after this stringent filte-
ring, there were still a number of alignments that
contained only two reference sequences from the CL-
Brener genome, but that belonged to these large gene
families – mucins, mucin-associated proteins (MASP),
trans-sialidase-like proteins, etc. These correspond to
cases where highly similar copies of members of a family
were separated from their paralogs during the clustering
or assembly steps. Finally, a number of alignments
(~6%) had only one reference sequence from the CL-
Brener hybrid. These cases may correspond to haploid
regions in the hybrid genome or to cases where two
highly divergent alleles were separated during the clus-
tering step.We then scanned the multiple sequence alignments
and identified columns containing sequence differ-
ences and/or indels. From the set of all alignments we
identified 325,355 sites with variation (putative single
nucleotide polymorphisms, or fixed differences), of
which 28,316 corresponded to small indels (Table 1).
These polymorphic sites provide representative infor-
mation on the diversity found in T. cruzi evolutionary
lineages TcI (Sylvio X10), TcVI (CL-Brener), but also in
lineages TcII and TcIII (represented by the variation
found within the CL-Brener hybrid).
Columns containing variation in a multiple sequence
alignment may correspond to polymorphic sites (SNPs) or
to sequencing errors. To discriminate between these possi-
bilities, we also analyzed the sequence neighborhood
around each potential SNP. Based on this analysis we found
302,390 SNPs (and 10,523 small indels) located in regions
with a low density of SNPs (good sequence neighborhoods,
with < 3 SNPs in a 10 bp window, see Methods). To further
assess the quality of the sequence around/in each SNP we
used a statistical software package (PolyBayes [34]) together
with quality values for each base that were derived from the
expected error rate for each sequence (described in
Methods). Using this approach we identified 288,957 SNPs
(and 1,480 small indels) that have both a high probability
according to PolyBayes (p > 0.7) and are located in good
sequence neighborhoods. Using this conservative set of
SNPs, we obtained a density of 2.4 SNPs per 100 bp for
T. cruzi coding regions.
The great majority (99%) of the observed SNPs were bi-
allelic (changing one specific nucleotide base for another),
however there were 2,990 tri-allelic SNPs (0.98%) and 10
tetra-allelic SNPs (0.0033%, P > 0.7). These are very inter-
esting SNPs that can be exploited in the design of strain
typing assays. One such assay, based on one tetra-allelic
and a number of tri-allelic SNPs has just been developed
using this information [31].
All this information is available in the Additional file 1:
Table S1 and has also been integrated in a new release of
the TcSNP database [32].
Experimental validation of candidate SNPs
To validate the strategy used in silico, and to assess the
quality of the SNPs and the probability of them being true
SNPs (as opposed to sequencing errors) we performed a
small scale re-sequencing study on 47 loci (see Table 2).
This set contained 1136 predicted SNPs with probabilities
(as reported by PolyBayes) ranging from 0 to 1, obtained
from genes with different numbers of predicted polymor-
phisms: low (e.g. 1–10 predicted SNPs), medium (11–25
SNPs) and high (> 25 SNPs). PCR amplification of selected
fragments from these loci was followed by direct sequen-
cing of the amplified products and identification of SNPs
from the raw chromatogram sequence data, including
Table 2 Validation of the SNP scoring scheme by
PCR-based re-sequencing
SNP score range Total
0–0.4 0.4–0.7 0.7–1.0 (0–1)
V NV V NV V NV V NV
No. of SNPs 9 63 25 8 996 35 1030 106
Percent validation 12.5 75.76 96.61 90.67
Fragments from selected loci were amplified by PCR and directly sequenced,
and SNPs were identified using PolyPhred after base-calling. The table shows
the number of SNPs identified in silico that have been validated (V) or not
validated (NV), grouped by their score.
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re-sequencing experiment allowed us to validate ~ 96% of
the predicted SNPs that had PolyBayes probabilities >= 0.7
(Table 2), whereas the success rate for SNPs with proba-
bilities between 0–0.4 fell to 12.5%. The results of this
small-scale study suggest that overall the scoring strategy
used to rank the SNPs worked well. We also identified 43
new heterozygous SNPs within the CL Brener strain (SNPs
not predicted by our in silico approach and not present in
the original release of the TcSNP database [32]) and 1,261
new SNPs from other T. cruzi strains (RO Cosentino,
L Panunzi, F Agüero, unpublished). The majority of these
new CL-Brener SNPs escaped the initial in silico prediction
because of artifacts in the assembly of the T. cruzi genome,
which resulted, for example, in a missing allele for an hypo-
thetical protein (TcCLB.511003.60) with high similarity to
the yeast ERG10 gene (Acetyl-CoA C-acetyltransferase). In
the T. cruzi genome database there is only one allele
reported for this gene. As a consequence, the few poly-
morphisms identified by our computational strategy were
derived from the comparison of this allele against a short
CL-Brener EST sequence (TENG0250, accession number
3258889, see alignment tcsnp:436105). However upon PCR
amplification from CL-Brener DNA, we were able to
uncover additional heterozygous polymorphisms (see
GenBank accession numbers HQ586976, and HQ586977).
Both pieces of evidence suggest that there is a second allele
that was probably merged or missed during genome assem-
bly. Apart from this case, this small scale re-sequencingTable 3 Transitions and transversions in T. cruzi
Substitutions Global (all) Synonymo
transitions (ts) AG + GA 104,421 45,652
CT + TC 96,208 55,758
transversions (tv) AC + CA 29,973 7,739
AT + TA 13,537 4,229
CG + GC 17,461 4,110
GT + TG 27,357 7,967
Ratio ts / tv 2.27 4.22
The set of high-quality SNPs was used to count the ocurrences of transitions and trexperiment confirmed the majority of the SNPs identified
in silico, which is in agreement with the expected sequence
coverage/quality of genomic and transcriptomic data used.
A complete table listing all loci analyzed, and their SNPs is
available in Additional file 2: Table S2.
Based on the results from this re-sequencing experi-
ment we decided to focus our analysis of genetic diver-
sity on the subset of high-quality SNPs (P > 0.7) that are
also located in regions of good sequence neighborhood.
This subset was therefore used throughout the study.
Because the candidate allelic copies of each reference
coding sequence are now aligned in our dataset, we use
the words gene and alignment interchangeably to refer
to the genomic loci represented by these sequences.
A first genome-wide look at the genetic diversity of T. cruzi
In the subset of high-quality SNPs, we first looked at the
types of changes observed at the DNA level: transitions
and transversions. Theoretically, there are twice the
number of possible transversions than transitions. How-
ever, because of the nature of the molecular mechanisms
involved in the generation of these mutations transitions
are found more frequently than transversions [36,37].
And T. cruzi was not exception. As observed previously
for rRNA genes [38] we observed an excess of transi-
tions (70.1%) over transversions (29.1%, see Table 3).
When analyzing the subset of high-quality SNPs at the
codon level, SNPs were more frequently observed at the
3rd codon position (53%), followed by the 1st codon
position (25%) and the 2nd (21%).
Functional characterization of polymorphic sites: nonsense
SNPs
Using the set of high quality SNPs (p > 0.7, in good
sequence neighborhoods) we observed 76,452 silent
(synonymous) SNPs, 99,552 non-synonymous SNPs and
161 non-sense SNPs – those introducing or removing stop
codons in proteins (see Table 1).
After manual inspection of alignments containing
nonsense SNPs, to filter out cases that could be explained
by genome assembly problems, we ended up with 113Observed counts








ansversions in different relevant partitions of the data.
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of which correspond to hypothetical proteins (80%, see
Additional file 3: Table S3). These nonsense polymorphisms
were produced by changes affecting different positions of
the codon (see Additional file 4: Figure S1).
Interestingly, we also observed a bias in the codon
position affected by these nonsense SNPs. Even though,
theoretically, we would expect nonsense SNPs in the 1st
base of a codon in 9 out of 23 nonsense SNPs (39%), we
observed a significantly higher number of nonsense SNPs
arising from mutation of the 1st base of a codon (66/110,
60%, p < 0.0005 Chi-square test for the comparison of the
observed-expected values for all 3 positions.
To further inspect whether these changes have been
fixed by evolution or were potentially recent events, we
analyzed these 113 loci in additional strains: the JR cl4
and Esmeraldo cl3 strains, taking advantage of prelimin-
ary assemblies available at the TriTrypDB resource [39].
These data is available in Additional file 3: Table S3.
Depending on which allele we consider as the ances-
tral allele, we can describe these SNPs as either intro-
ducing a premature stop codon (therefore producing a
truncated protein) or as generating a read-through
codon (therefore producing a longer product). The
comparison of nonsense mutations in the available
data suggest that in 3 cases (hypothetical proteins
TcCLB.509767.140, TcCLB.503905.50, and TcCLB.5066
91.70) the ancestral state of the codon was most prob-
ably a STOP (readily identified in 5 out of 6 strains)
that was changed into a read-through codon in one
strain/lineage only. In other cases the situation might
be similar (TcCLB.506773.80, TcCLB.510533.80, TcCLB.
508207.170, TcCLB.503525.4, TcCLB.508567.49, TcCLB
.505229.20, all hypothetical proteins; and TcCLB.50818
1.140, an inorganic pyrophosphatase), although the
corresponding CDS was missing from one of the
strains. In contrast, in 44 cases (39%) the nonsense
mutation was only observed once, and can therefore
correspond to the alternative case, in which the ances-
tral codon was replaced by a premature stop, therefore
generating a truncated protein product.
Analysis of the these cases, revealed that the majority of
them (77%) contained the nonsense SNP in the final 10% of
the corresponding coding sequence, near the 3’ end of the
other allele (see Table S3), and therefore may not be asso-
ciated with large functional changes. However, in a few
cases the identified nonsense SNPs are producing predicted
disruptive changes.
In the case of a putative GDP-mannose 4,6 dehydratase
(alignment tcsnp:439464, TcCLB.503881.20), the nonsense
SNP, present only in strains from the TcI lineage, is located
near the N-terminus of the protein, therefore theoretically
resulting in a complete truncation. Although there is a
downstream ATG that could be used to produce a productwith only a 11% reduction of its size, this product would
lack the conserved NAD(P) nucleotide binding motif
GGxGxxG [40], and therefore we believe it cannot produce
a functional protein. In another case (alignment tcsnp:43
8249, including reference sequences TcCLB.511907.190 and
TcCLB.506801.70), the presence of a nonsense SNP in one
CL-Brener allele, causes the shorter TcCLB.506801.70 allele
to lose a potential glycosylphosphatidyl inositol C-terminal
anchor sequence, generating a potential significant change
in localization of the protein (secreted vs membrane
anchored product). The number of SNPs identified
between these two sequences is approximately twice the
average found in other sequences (117 SNPs, 47 non-
synonymous SNPs). This, together with the observed diffe-
rences in sub-cellular targeting signals, suggests that these
alleles may have divergent functions. Another case invol-
ving a potential change in sub-cellular localization due to a
missing GPI-anchor in one allele, was identified in align-
ment tcsnp:442281 (containing reference sequences
TcCLB.508951.80 and TcCLB.510121.80), encoding a puta-
tive proteins that belongs to the RNI-like superfamily of
leucine-rich containing proteins, which are thought to me-
diate protein-protein interactions.
Distribution of SNPs in T. cruzi coding regions
Next, we analyzed the distribution of SNPs along the
coding region, and in the context of different sequence fea-
tures: trans-membrane domains, signal peptides, globular
vs unstructured regions. We reasoned that the selection
acting on the gene might be different in these different
regions or domains. Based on this idea, we performed a
number of comparisons, evaluating differences in the
density of synonymous and non-synonymous changes in
one of these domains vs the rest of the protein. However,
although some significant signal can be observed when per-
forming pairwise comparisons (e.g. between the Esmeraldo-
like and Non-Esmeraldo-like alleles of CL-Brener), these
differences are not significant when using the complete
data that includes alleles from TcI, TcII (Esmeraldo, and
Esmeraldo-like from CL-Brener), TcIII (non-Esmeraldo-like
alleles from CL-Brener), and TcVI (CL-Brener).
One of the features analyzed, was the presence of SNPs
in natively unstructured domains. Several recent papers
report an observation that natively unfolded domains can
support higher non-synonymous substitution rates [41,42].
Based on predictions made using IUPred [41] we identified
globular and natively unstructured domains in T. cruzi
proteins (globular regions ranged from 10 to 90% of the
protein). A comparison of the SNP density found in these
regions showed no statistically significant differences (data
in Additional file 5: Figure S2). However, we did observe a
great dispersion in the density of SNPs in non-globular
regions, with more outliers with higher densities of non-
synonymous SNPs in this category. Analysis of the
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in transporters, kinases (including some 13 protein kinases
with no known function) and hydrolases (including a num-
ber of ubiquitin hydrolases). A particularly striking outlier
is the TcCLB.506553.20 gene encoding a bromodomain
containing protein, with a restricted phylogenetic distribu-
tion. As can be seen in Figure 1 (C-terminal domain) and
in the Additional file 6 (complete alignment), in which we
also analyzed the alleles present in preliminary assemblies
of the JR cl4 and Esmeraldo cl3 genomes, 70 out of a total
of 94 SNPs (87 of which are non-synonymous), were
located in a natively unstructured C-terminal tail. Besides
being present in all trypanosomatids, this gene is also
present in Trichomonas and in a a few other organisms
such as Caenorhabditis, Cryptosporidium, and in one plant
(Oryza sativa).
Another interesting gene showing a striking accu-
mulation of non-synonymous changes in a natively
unstructured domain is the A2Rel-like protein of
T. cruzi (alignment tcsnp:435203, alleles TcCLB.
506859.110, TcCLB.511815.80), which was first des-
cribed in Leishmania [43,44]. In this case the majority
of SNPs identified are located in a disordered N-terminal
domain, as predicted by IUPred.Figure 1 A natively unstructured domain accumulating non-synonym
position 550 in the alignment) showing the C-terminal, natively unstructure
other strains. Asteriks indicate non-synonymous changes. The nucleotide m
aminoacid translation as a guide [71]. The complete multiple sequence aligAssessment of selection pressure in T. Cruzi coding genes
Because SNPs identified in this work represent variation
observed within a species, we decided to use the nucleotide
diversity indicator π as an estimate of selection [45,46]. In
our set of high-quality alignments (at most 2 reference
coding sequences from the CL-Brener genome), π ranged
between 0 and 0.15 (Figure 2).
Not taking into account loci corresponding to singleton
sequences (those not grouped and aligned with any other
sequence), the remaining loci with nil values of π were
those for which we could not identify high-quality SNPs
(for example sequences aligned against 100% identical
copies and/or mRNAs). As seen in Figure 2, there is an ap-
parent enrichment of alignments with no SNPs identified.
By inspecting the annotation of these genes, it is clear that
many of these cases correspond to alignments containing
highly identical copies of genes from large families. It has
been observed already that many of these genes
(e.g. mucins) are organized in tandem arrays, where copies
of the array display unusually high nucleotide identity
values [47]. It is clear that the diversity observed in one of
these alignments (where highly identical sequences from a
larger family were clustered and aligned together) is not
representative of the overall diversity that can be seen atous changes. Section of a multiple sequence alignment (starting at
d, region of the TcCLB.506553.20 gene, and its allelic counterparts in
ultiple sequence alignment was obtained with TranslatorX, using the

















Figure 2 Allelic divergence observed in T. cruzi. Histogram of nucleotide diversity (π), showing the distribution of allelic variation in the
analyzed data. Alignments (loci) meeting our criteria for good quality (see main text) and containing no more than 2 reference coding sequences
from the CL-Brener genome, were used to calculate the nucleotide diversity values in the figure. The values of π were normalized over the
effective length of the alignment (see Methods). For the histogram, the values were binned as shown in the x axis. Only values of π < 0.1,
corresponding to 7,624 alignments (99.8%) were included in the graphic.
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from these cases, alignments with low π values were
those of ribosomal proteins, histones and cytochromes
among others.
To assess the functional relevance of the nucleotide diver-
sity indicator, we looked at the distribution of π in differ-
ent functional contexts: the functional annotation of the
T. cruzi genome using the Molecular Function ontology
(from the GO Gene Ontology); and the functional map-
ping of T. cruzi enzymes in metabolic pathways accor-
ding to the KEGG Metabolic Pathways database (data
available in Additional file 7: Table S4 and Additional file 8:
Table S5). First, using a subset of terms from the Gene
Ontology (GO Slim) [48] we grouped 2,158 alignments
(loci) containing GO annotation into 27 broad classes as
defined by their parent GO terms from the Molecular Func-
tion ontology. There were significant differences in the π
values when comparing all classes using the non-parametric
Kruskal-Wallis test (p < 0,0001, a posteriori test p < 0.05;
see Figure 3). The categories showing less diversity were
those with functions in oxidative stress response, protein
ubiquitination, and those involved in RNA processing and
translation. On the other extreme, classes showing a high
nucleotide diversity were those corresponding to integralmembrane proteins, ion binding (mostly Ca++) and retro-
transposons. In all cases, we observed a significant disper-
sion of the π indicator for any one class. Secondly, we
performed a similar analysis on genes with assigned EC
numbers (655 alignments) that were mapped onto KEGG
pathways. In this case, genes that participate in transcription
and protein degradation (proteasome) showed less
nucleotide diversity, similar to what we observed for
GOSlim classes; whereas genes involved in glycan synthesis
and degradation, metabolism of co-factors and vitamins,
and xenobiotic metabolism showed a higher nucleotide
diversity (Kruskal-Wallis test, p < 0.004, a posteriori test
p < 0.05; see Figure 4).
The observed dispersion of the apparent selection pres-
sure acting on a given metabolic pathway is not surprising,
as the importance of different steps in the pathway
(e.g. their centrality, connectivity) is not homogeneous. In
the case of T. cruzi, the sterol biosynthesis pathway (one of
the few validated pathways for drug development) is a nice
example of this observation. Interestingly, current validated
targets (e.g. the lanosterol demethylase and the C-24 sterol
reductase) display low numbers of non-synonymous
changes (10% and 28% non-synonymous SNPs, and
π = 0.015, and 0.0065, respectively). However, at the same
Figure 3 Genetic diversity in functional classes (Gene Ontology). Alignments containing genes annotated with GO terms (2,158 alignments)
were grouped into higher-level classes based on the GO ontology of terms using GOSlim, and also based on nucleotide diversity ([0–0.008);
[0.008–0.016); [0.016–0.024); [0.024–0.032); >= 0.032). Differences between categories were observed and are marked in the figure (Kruskal-Wallis
test, P < 0.0001; a posteriori test, P < 0.05). Different letters indicate significant differences.
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desaturase (alignment tcsnp: 440342) apparently not
required by the intracellular amastigotes [49] is accumu-
lating more non-synonymous polymorphisms (53% non-
synonymous SNPs, π = 0.012, although still at a level corre-
sponding to a neutral accumulation of changes).
Predicted druggable targets display less genetic diversity in
T. cruzi
Attractive targets for drug development have to meet a
number of requirements. The most important of these is
the essentiality of the target for survival of the parasite
within the host. However, a number of other criteria are
often used to prioritize drug targets [50], druggability –
knowledge about inhibition or modulation of the target by
a small molecule – being one such criteria. For human
pathogens, the druggability of targets in whole genomes
has been predicted based on their similarity against a data-
base of known druggable targets, and on the presence of a
number of sequence, and structural features [51]. Drug-
gability predictions are available from the TDR Targets
database [52] in the form of a druggability index associated
with each target that goes from 0 (not druggable, or lack ofprior information on druggability) to 1 (druggable, highly
similar to a target with a known inhibitor/drug). For
T. cruzi druggability predictions allowed the identification
of 173 loci with a druggability index > 0.6.
In the context of the selection of drug targets for drug
discovery, the evolutionary forces acting on a gene may
be used as a surrogate marker for essentiality or to as-
sess the risk of development of drug resistance. Taking
advantage of the genetic variation identified within the
T. cruzi genome we analyzed the apparent selection
pressure in predicted druggable targets (druggability
index >= 0.6) vs the rest of the genome – genes enco-
ding products that are either not druggable (druggability
index < 0.6) or for which there are currently no informa-
tion about their druggability (5,231 genes). For this
analysis we used the nucleotide diversity indicator π, or
the dN/dS indicator (not shown). We then analyzed the
distribution of π in these two groups of genes (see
Figure 5). The two distributions were statistically diffe-
rent (Wilcoxon test, P < 0.0001), with the distribution of
druggable targets shifted to lower values of π. This
showed that a significant number of targets that are pre-
dicted to be druggable in T. cruzi displayed less variation
Figure 4 Genetic diversity in metabolic pathways. 657 genes with EC numbers were mapped to the corresponding metabolic pathways in
the KEGG database [72] and sorted based on the nucleotide diversity (π) estimator of the selection acting on the gene. Different letters (on the
right) mean statistically significant differences (Kruskal-Wallis test, P < 0.0013; a posteriori test P < 0.05).
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may not be surprising, as many druggable targets are
highly conserved genes with housekeeping cellular func-
tions [53]. However, this result also highlights the fact
that there are many genes, with low nucleotide diversity
values, for which we don’t have information about their
druggability (e.g. overlapping red/gray bars in quartile 1
of the distributions in Figure 5). Targets in this portion
of the curve might represent novel classes of targets, not
previously explored (e.g. parasite specific targets), and
thus worthy of consideration.
Following this reasoning, we suggest that it may be
helpful to include genetic diversity information in target
prioritization strategies, such as those discussed by
Crowther et al. [54]. We therefore used the genetic
diversity information described in this work to prioritize
T. cruzi targets (see strategy in Methods), using a genetic
diversity score based on a normalized inversion of the
nucleotide diversity value. With this scoring system,
genes with a low π value will attain a higher score, and
vice versa (see Methods). The result of this prioritization
is available from Additional file 9: Table S6. In this list,
three validated targets appear within the top 12 targets:
the lanosterol 14-α demethylase (target of triazoles), the
trypanothione reductase (essential in all trypanosomatidsstudied so far), and the protein farnesyltransferase (target
of the drug tipifarnib), therefore serving as controls of the
prioritization strategy. The list highlights a number of
interesting targets, some of which are currently unex-
plored in T. cruzi. The top ranked target in this list is a
dihydrolipoamide dehydrogenase (EC 1.8.1.4), an enzyme
usually involved in both energy generation and defense
mechanisms against oxidative and nitrosative attacks. Se-
lective inhibitors for this enzyme have been identified in
T. cruzi [55] and Mycobacterium tuberculosis [56]. The
allelic variants identified display limited variation, with a π
value of 0.01, and only 4 non-synonymous SNPs. Other
interesting targets displaying low nucleotide diversity
values include the RNA polymerase III (the target of
tagetitoxin), an S-adenosylhomocysteine hydrolase that
displays large biochemical differences with its human
orthologue [57], a unique deoxyuridine triphosphatase
[58], an inorganic pyrophosphatase, and a number of ami-
noacyl tRNA synthetases, amongst others. A detailed ana-
lysis of this prioritized list is not within the scope of this
work and will certainly be done by interested researchers
in the field. However, it is worthwile to mention that using
genetic information provides an additional, independent,
measure to prioritize targets, selecting those that are
under apparent purifying selection.
Figure 5 Genetic diversity of T. cruzi druggable genes. The plot shows the distribution of the nucleotide diversity (π) estimator for T. cruzi
druggable genes (125 genes, druggability index >= 0.6 [70]), and for genes that are either non-druggable or lack information about their
druggability. The two distributions are statistically different according to the Wilcoxon test (P < 0,0001).
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Identification and ranking of SNPs
In this study we identified hundreds of thousands of candi-
date SNPs located primarily in single-copy coding regions
of the T. cruzi genome. The scoring strategy used to evalu-
ate putative SNPs in the absence of raw chromatogram data
proved to work reasonably well, as we were able to confirm
>= 96% of the SNPs having a probability value >= 0.7 by
re-sequencing. The genome-wide data shows that the
T. cruzi genome is highly polymorphic, with almost 5
polymorphic sites every 200 bp (2.4%). This figure is similar,
though not identical, to that reported by El-Sayed et al. for
the CL-Brener whole genome (2%) [24]. However, there are
differences in both strategies. In our case, the analysis is
focused mostly on coding regions. This would have resulted
in a slightly lower nucleotide diversity value if we had
limited our analysis to the CL-Brener hybrid. However, by
inclusion of data from other strains, we effectively sampled
more genetic space, therefore arriving at a significantly
higher diversity for protein coding regions.
The T. cruzi genome is highly repetitive [24,33] with
many large gene families often organized in tandem
arrays. Assembly of this type of genomes from whole
DNA shotgun is expected to be difficult [59], and the T.
cruzi genome was no exception [24]. This could have
made the identification of SNPs problematic, or caused
the identification of false SNPs (misassembly, and/or
sequencing errors). Nonetheless, the high sequencecoverage attained (~ 11X for both CL-Brener and Sylvio
X10 genomes) resulted in high confidence sequence
(at the base level) for most of the single-copy portions of
the genome. We have targeted these portions of the
genome for mapping polymorphic sites, reasoning that
these are the regions with a higher quality. This is
certainly not true for all cases, as has been recently
noted [60]. However, our strategy for validation of puta-
tive SNPs by re-sequencing worked reasonably well. The
methodology was based on direct sequencing of PCR
amplification products, and except for three cases, we
did not observe amplification of bands of different sizes
or an excess of heterozygous peaks in the sequence
traces, which would be suggestive of amplification of a
mixture of genes from different loci (e.g. paralogous
copies). From a total of 47 loci that were selected for re-
sequencing, one was discarded due to the presence of
amplification products of different sizes, another was the
result of an amplification of a tandem array containing
two copies of the targeted gene (N-acetylglucosaminyl-
phosphatidylinositol- deacetylase, putative; TcCLB.51148
1.40), while in the third case the excess of heterozygous
sites revealed the missing allele for a single-copy gene
(TcCLB.511003.60, see Results). Except for these cases,
all other targeted loci showed the expected heterozygos-
ity based on the in silico comparison of the two CL-
Brener haplotypes. Notwithstanding this, the overall ana-
lysis presented in this paper is clearly focused on a core
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way in which the bioinformatic strategy was devised, we
are probably underestimating the number of highly poly-
morphic genes. Theoretically, single copy genes with
highly divergent alleles could end up in separate clusters,
and therefore in different alignments (or as singleton
sequences), due to their high number of nucleotide dif-
ferences. Our bioinformatics strategy, using a second
BLAST stage to detect these cases worked well overall,
but a number of such cases did escape the initial auto-
mated analysis, and have been corrected by manual mer-
ging of alignments. Therefore, we cannot rule out the
possibility of missing additional cases.
Polymorphisms or fixed differences?
When comparing nucleotide changes between different
species, it is mostly correct to assume that these differ-
ences are fixed (i.e. they are substitutions or mutations).
In our particular case, we are analyzing changes within a
species. Therefore we have chosen to call all observed
nucleotide changes as polymorphisms or SNPs. These
distinctions affect the choice of different estimates of
selection, such as dN (the number of non-synonymous
changes per non-synonymous site) and dS (the number
of synonymous changes per synonymous site), or the
nucleotide diversity (π) [46]. In this work we have
decided to include results based on the use of the
nucleotide diversity (π) as an estimate of selection
instead of the dN/dS ratio. However, it should be noted
that published results [21], and our own data from an
ongoing re-sequencing study focussed on selected loci,
show that a significant percentage of the identified
changes can be verified by re-sequencing a different
strain from the same evolutionary lineage. This percent-
age can be as high as ~ 96% for changes identified be-
tween the CL-Brener haplotypes (verified in strains from
the corresponding parental lineages (R. Cosentino, L.
Panunzi, F. Agüero, unpublished results), strongly sug-
gesting that the great majority of the polymorphisms
identified in this study are actually fixed differences. This
is also in agreement with recent comparisons of two
T. brucei genomes [61]. Nonetheless, the conclusions of
analyses performed in this work (see Figures 2, 3, 4, and 5),
obtained using the π indicator, do not change subtantially
if we use the dN/dS ratio instead (data not shown).
SNP types, functional changes
When we analyzed the set of high-quality SNPs identi-
fied according to the type of change they introduce at
the protein level, we observed a slightly higher number
of non-synonymous SNPs. This result is in agreement
with similar observations made in other protozoan
organisms: i) the comparison of the genomes of T. brucei
brucei and T. brucei gambiense [61]; and ii) SNPsbetween Toxoplasma gondii strains from the 3 main evo-
lutionary lineages available at ToxoDB [62]. However,
this is in contrast to observations in other eukaryotes,
such as humans and helminths (Schistosoma mansoni
[63]) where a higher number of synonymous changes is
observed. This observation most likely reflects the accu-
mulation of changes in T. cruzi and the other protozoan
genomes through a large time of divergence. The fact
that most of the allelic diversity observed within the CL-
Brener hybrid has been acquired through the proposed
hybridization events between ancestral individuals from
lineages TcII and TcIII, imply that the observed genetic
diversity within the CL-Brener clone corresponds to the
expected diversity between T. cruzi DTUs TcII and TcIII.
As reported recently in an analysis of 32 loci in an
expanded panel of strains, the distances between the
Esmeraldo-like (TcII) and non-Esmeraldo-like (TcIII)
alleles of CL-Brener were the maximum observed within
T. cruzi [21]. The estimates for time of divergence for
these ancestral lineages, therefore, are in agreement with
a large time of divergence, justifying the observed num-
ber of synonymous and non-synonymous sites.
The distribution of synonymous SNPs along the coding
regions was uniform. However in the case of non-
synonymous SNPs, we observed a tendency for accumula-
tion in signal-peptides, trans-membrane domains, and
cleaved C-terminal tails (C-termini that are cleaved after
the addition of glycosylphosphatidyl inositol anchors).
Although not statistically significant at the genome scale,
we did find a number of cases in which there was striking
contrast in the accumulation of non-synonymous changes
between natively unstructured vs globular regions.
A similar accumulation of non-synonymous changes in
these regions has been reported by others in different bio-
logical models. In yeast, a survey of SNP data from 64
strains of Saccharomyces cerevisiae suggest that this accu-
mulation is particularly associated with proteins whose
function is related to adaptive processes [64]. Although
T. cruzi lags behind S. cerevisiae in functional charac-
terization of its protein coding gene set, it is tempting to
speculate that a similar trend is likely to be observed.
Proteins carrying natively unstructured or disordered
domains, such as the human transcriptional regulator p53,
are often at the center of large signaling networks, and
serve as organizing scaffolds for protein complexes
[65,66]. In our dataset, a number of such proteins can be
readily identified (see Results). One of these is the A2rel
protein first described in Leishmania donovani [43,44].
This is a protein of unknown function, that is expressed in
the amastigote stages infecting host cells, and that has
been implied in the process of visceralization of infection,
as it is absent in Leishmania species causing cutaneous
leishmaniasis. Recently, this protein has been shown to be
upregulated during a temperature shift similar to that
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insect to the vertebrate host (see Table 3 in [67]). It would
be interesting to analyze the function of this protein in
T. cruzi and also the functional consequences of the
observed allelic diversity.
As reviewed recently by Uversky and colleagues [65],
intrinsically disordered proteins are particularly attract-
ive targets for modulating protein-protein interactions.
However, in light of the observed allelic diversity in
these domains, it would be important to take this into
consideration when assaying these proteins.Estimates of T. cruzi genetic diversity
The genetic diversity identified in this work gives a broad
overview of the diversity present within the T. cruzi
species, at a genomic scale. Based on the genome data
analyzed herein, and on the limited re-sequencing of
selected loci in a panel of representative strains (minimum
of 3 per DTU [31], as well as other unpublished data,
including the draft genomes of TcII and TcI strains), we
estimate that ~ 50-60% of the genetic diversity of the spe-
cies has been sampled. This is of course a gross estimate,
but the support for this figure comes from the following
observations. First, in our re-sequencing experiments we
have found that 42% of the nucleotide changes can be dis-
covered just by analyzing the CL-Brener hybrid. This is in
agreement with other studies using a panel of reference
strains [21]. This diversity corresponds to that observed
between extant TcII and TcIII strains, and appears to be
the maximal divergence observed between evolutionary
lineages [21]. Sencondly, when re-sequencing the same
loci in TcI strains, it was possible to identify new add-
itional SNPs, corresponding to ~ 18% of the total genetic
diversity that can be uncovered in this panel of 18 strains.
However, 82% of the observed SNPs had already been
identified by analyzing the CL-Brener hybrid genome. A
similar figure (~17% new SNPs) is obtained for TcIV
strains. However, by sequencing TcII or TcIII strains, only
a minimal number of additional SNPs are uncovered, cor-
responding to 3-4% of the total. This reflects the fact that
the majority of these nucleotide changes have already been
identified from CL-Brener alleles. The same low rate of
discovery of new SNPs is observed when re-sequencing
strains from the TcV lineage. Strains from this lineage
show very limited genetic diversity when compared with
the TcVI strains. Although these observations are based
on a small scale re-sequencing study, the same trend can
be observed when analyzing additional loci from the draft
genomic data for TcI and TcII strains (data not shown).
According to this analysis, the next step to significantly in-
crease the coverage of the genetic diversity identified for
T. cruzi, should be the analysis of complete genomic or
transcriptomic data from a TcIV strain.Conclusions
By taking advantage of the genomic and transcriptomic
sequence data from a number of strains representative of
different evolutionary lineages of T. cruzi, we have com-
piled an initial map of genetic diversity for this important
parasite, focused mostly on protein coding, single-copy
regions of the genome. The picture emerging from this
analysis reflects the highly divergent nature of the ances-
tral haplotypes of the hybrid CL-Brener strain. However,
the analysis also shows that there is a highly conserved
core of the genome under apparent purifying selection,
and highlights a number of genes and domains deviating
from this extreme. The work represents the first genome-
wide map of genetic diversity for T. cruzi, covering about
half of the estimated nucleotide diversity of the species.
Methods
Data sources
Data used for SNP identification included: the T. cruzi
CL-Brener (DTU/genotype TcVI) and Sylvio X10 (DTU/
genotype TcI) genomes (coding sequences, contigs, scaf-
folds; obtained from GenBank using the accession num-
bers AAHK00000000 [24], and ADWP00000000 [28],
respectively), RNA-seq (transcriptomic) data from the
TcAdriana strain (DTU TcI, obtained by 454 high-
throughput sequencing of an epimastigote cDNA library,
Westeergard G and Vazquez MP, manuscript in prepar-
ation), partial shotgun (genomic) data from the Esmeraldo
strain (DTU TcII, obtained from the NCBI Sequence Read
Archive), as well as other T. cruzi sequences obtained
from GenBank in May, 2007 (see Table 1). T. cruzi ESTs
were obtained from dbEST and manually curated to ex-
tract information about their source (strain) [68]. To val-
idate SNPs identified in a limited number of genes, we
have checked preliminary assemblies from the JRcl4
(DTU TcI), and Esmeraldo cl3 (DTU TcII) strains avail-
able at the TriTrypDB resource [39].
Sequence clustering and alignment
Before clustering, sequences were screened against a
library of T. cruzi repetitive elements and vector (plasmid)
sequences and the corresponding matching regions were
masked [33]. Sequences containing at least 50 bp of non-
masked bases were further processed. T. cruzi coding
sequences from the genome project (CDS), and other nu-
cleotide (mRNA, EST, genomic DNA) sequences were
mapped to the reference genome sequence scaffolds using
BLAT [69]. Sequences were grouped in clusters based on
the following stringent mapping: any two sequences
overlapping in their mapping against a given reference
genome scaffold were put together into the same cluster.
Subsequently, multiple sequence alignments (MSAs)
were obtained for each cluster using phrap (http://www.
phrap.org). When more than one multiple sequence
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quences, we manually merged the alignments if they met
the following criteria: i) the sequences from the reference
genome did not have an assembly warning note; ii) there
were no more than two reference coding sequences from
the CL-Brener genome in the merged alignment; and iii)
the divergence between the reference sequences, as judged
by manual inspection, would justify the merging (for ex-
ample, manual inspection of these cases allowed us to
merge cases of reference sequences differing only in the
extension of their 5’ ends – usually arising from different
annotation of the translational start codon in each allele –
or in indels larger than a couple of codons, which would
otherwise cause the sequences to end up in separate
contigs due to the stringent criteria used in this step).
Genomic data from the Sylvio X10 draft assembly, and
from reconstructed transcripts from the TcAdriana 454
RNA-seq data were mapped against these CL-Brener
reference alignments. Finally, the quality of each MSA was
assessed using two parameters: the % identity, and an esti-
mate of the effective length of the alignment. This latter
figure provides the percentage of columns in the align-
ment where the alignment depth >= 2. MSAs with a %
identity > 95% were considered further. MSAs that did
not meet these criteria were manually inspected to evalu-
ate further manual editing (split alignments). Because in
some cases alignments might contain sequences that are
shorter at one or both ends, the effective length of the
alignment (ignoring regions covered by a single sequence)
was used to compute alignment attributes, such as the
SNP density.
SNP identification and scoring
Multiple sequence alignments were scanned using a cus-
tom Perl script to identify polymorphic columns. These
putative SNPs were analyzed using PolyBayes [34] to ob-
tain a numeric score for each SNP (the probability of this
being a true polymorphism). PolyBayes can use individual
base quality values for the calculation of SNP probabilities,
but because original chromatogram data is not available
for all sequences, we have assigned arbitrary base quality
values to these sequences. These arbitrary quality values
were derived based on the estimated sequencing error rate
for the different types of sequences used: EST sequences
were assigned an arbitrary base quality value of 20 (1 error
per 100 bases), which is typical for single-pass, unedited
sequences; while sequences derived from individual sub-
missions to GenBank were assigned a quality value of 30
(1 error per 1000 bases). Sequences derived from the
genome project were assigned a base quality value of 40
(1 error per 10,000 bases), based on the fact that they are
derived from an ~11X coverage of the genome.
The nucleotide diversity indicator π (average propor-
tion of nucleotide differences between all possible pairsof sequences) [45] was calculated for each alignment
using the effective length of the multiple sequence align-
ment (not considering regions of the alignment where
the depth was 1) as the total number of available sites.
SNP validation by re-sequencing
DNA from the CL-Brener and Sylvio X10 strains of
T. cruzi was prepared by extraction with DNAZol
(Invitrogen), according to the protocol provided by the
supplier. To select the regions for amplification, we
started from a multiple sequence alignment containing
putative polymorphic sites, and identified regions in the
alignment that correspond to blocks of conserved se-
quence (100% identity, devoid of indels and putative
SNPs). Two such regions separated by a block of 400–
600 bp and containing at least 2 putative polymorphic
sites were selected in order to design the corresponding
5’ and 3’ amplification primers. The genes and oligonu-
cleotides used for PCR-based re-sequencing are listed in
the Additional file 10: Table S7. These oligonucleotide
primers were used both for the amplification and
sequencing reactions. Each 25 μl reaction was composed
of 2.5 U of Taq polymerase (Invitrogen), 2.5 μl 10X Buf-
fer (Invitrogen), 2 μl 2.5 mM dNTPs (Invitrogen), 0.8 μl
50 mM MgCl2 (Invitrogen) and 16.2 μl MiliQ water
(Millipore). Amplification products were checked in
1.2% agarose gels stained with ethidium bromide and if a
single amplification product was observed, an aliquot of
the amplification reaction was treated with Exonuclease I
(Fermentas) and Shrimp Alkaline Phosphatase (SAP)
(Fermentas) and two sequencing reactions were prepared,
each with one of the primers used for the amplification of
the product. Sequencing was carried out in an Applied
Biosystems 3130 capillary sequencer using a Big-Dye ter-
minator cycle sequencing kit, according to the instruc-
tions of the manufacturer. Chromatogram data derived
from these reactions was analyzed using PolyPhred [35]
to identify polymorphisms, including heterozygous peaks.
Information was collected for both homozygous high
quality discrepancies between sequences and heterozy-
gous peaks within sequences.
Target prioritization strategy
To prioritize targets, we used the functionality available
within the TDR Targets database to assign different
scores to genes depending on the presence/absence of
different attributes or features [54,70]. Briefly, in TDR
Targets (http://tdrtargets.org) we ran a query for each
selected attribute to filter the genome and obtain a subset
of genes (for example, those with orthologs in other kine-
toplastids). After running all queries we assigned different
numerical weights to each subset of genes (see below),
and calculated a weighted union of these lists. The final
score of a gene is the cumulative sum of the weights
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possibility of obtaining weighted unions (instead of inter-
sections) allowed us to make a comprehensive prio-
ritization of the T. cruzi genome using a large number of
criteria. The following attributes were evaluated (the
score/penalty applied to each criteria is available in
Additional file 9: Table S6): essentiality of bacterial (E. coli,
M. tuberculosis), yeast (S. cerevisiae) or C. elegans) ortho-
logs; absence of orthologs in mammals (human/mouse);
presence of orthologs in other kinetoplastids (T. brucei,
L. major); proteomic evidence of expression in amasti-
gotes and trypomastigotes (data obtained form TriTrypDB
[39]); availability of literature records for the target; avail-
ability of biochemical assays for the target; precedence for
production of soluble recombinant protein; low mole-
cular weight (<100 kDa); target is an enzyme (has an EC
number); target has a solved 3D structure or a calculated
3D model; target has trans-membrane spanning domains
(penalized); target is present in multiple copies (> 2 copies
per haploid genome) (penalized); presence of a signal pep-
tide (ER-secretory route) (penalized); presence of a GPI
signal sequence (penalized). To further improve on this
prioritization, we assigned positive scores to genes that are
likely to be under purifying selection (low π values). The
score for each gene was calculated using a sigmoid
normalization function:
score π; kð Þ ¼ 1þ 20π=k  50
where π is the nucleotide diversity and k is a scaling factor
(0.08 in this case). A list of genes with their corresponding
scores calculated in this way was uploaded to TDR Targets
as a tab-delimited text file, to finish the prioritization
strategy. The result of this prioritization is shown in the
Additional file 9: Table S6 and is also available from TDR
Targets (http://tdrtargets.org/published/browse/423).
Locus identifiers
According to recent changes related to standardization
in trypanosomatid locus identifiers used in community
databases, all such T. cruzi identifiers referenced in this
work appear in their current shorter form, e.g.
TcCLB.507853.10 (equivalent to the old locus identifier
Tc00.1047053507853.10).
Data deposition
The sequences reported in this paper have been deposited
in the GenBank database (accession numbers: HQ586966-
HQ587039; SNPs identified in this paper have been
deposited in the dbSNP database (submission batch id:
1050246) and are also available from the TcSNP database
at http://snps.tcruzi.org. All TcSNP alignment identifiers
mentioned in this work (e.g. tcsnp:438249) can be
accessed using the following standard URI, and replacingthe alignment identifier (e.g. 438249) in each case: http://
snps.tcruzi.org/genes/alignment?assembly_id=438249.
Additional files
Additional file 1: Table S1. Complete list of alignments used for the
detection of SNPs in this work. The table contains information on the
alignments and the type and number of SNPs identified in each case.
The Calc/Excel workbook contains two spreadhseets: the first contains a
complete legend, describing all columns in detail; the second contains
the data itself.
Additional file 2: Table S2. Experimental validation of identified SNPs
by PCR-based re-sequencing. The table shows, for each loci analyzed, the
number of SNPs identified in silico, as well as those that have been
validated (V) or not (NV) by re-sequencing.
Additional file 3: Table S3. List of nonsense polymorphisms identified
in this work. For each nonsense SNP identified we show the
corresponding codon for each genome/strain analyzed, and N/A if the
gene has not been identified in a dataset.
Additional file 4: Figure S1. Nonsense SNPs observed in the CL-Brener
genome. (A) List of observed nonsense SNPs, sorted by descending
frequency. Nonsense changes shown in black require only a single
mutation to produce a stop codon. SNPs shown in color require
changing two bases in the same codon (Ts = transition; Tv =
transversion). (B) List of observed nonsense mutations, by type (Ts/Tv).
(C) Genetic code showing all possible single base changes that would
produce a stop codon, and those observed in T. cruzi.
Additional file 5: Figure S2. SNP density in globular vs unstructured
protein domains. The density of SNPs in globular vs intrinsically
unstructured regions (predicted by IUPred) was compared for
synonymous, and non-synonymous changes (left and middle panels). A
third panel (right) showing all SNPs is shown for comparison. In all cases
the differences between the distribution were not statistically different.
Additional file 6: Figure S3. A natively unstructured domain
accumulating non-synonymous changes (complete alignment). Multiple
sequence alignment showing the TcCLB.506553.20 gene, and its allelic
counterparts in other strains (Additional file 10: Figure S3). The gene has
a globular N-terminal domain, and an intrinsically unstructured C-terminal
domain, as predicted by IUPred [73]. This figure contains the complete
alignment shown in Figure 1.
Additional file 7: Table S4. GO Slim annotation of alignments used for
the detection of SNPs in this work.
Additional file 8: Table S5. KEGG pathway mapping of alignments
used for the detection of SNPs in this work.
Additional file 9: Table S6. Drug target prioritization using a score
based on the nucleotide diversity estimator (π) as one of the main
driving criteria. The spreadhsheet contains the top 300 targets. The
complete ranked proteome, as well as the individual queries can be
accessed online at http://tdrtargets.org/published/browse/t/423.
Additional file 10: Table S7. Primers and amplification products used
in the SNP validation experiment.
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